Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Subscribe Now
/Free Sign Up
 0
🧠 Watchlist Winners: Copy Legendary Investors' Portfolios in One Click COPY FOR FREE
Close

Relief Therapeutics Holding SA (RLFTF)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
2.54 -0.36    -12.41%
13/09 - Closed. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 9,229
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 2.47 - 2.65
Relief Therapeutics 2.54 -0.36 -12.41%

SIX:RLFTF Financials

 
A brief overview of the SIX:RLFB financials. This summary provides an overview of the most significant critical numbers from each of its financial reports, including the income statement, balance sheet, and cash flow statement. Additionally, it features several financial ratios that provide insight into the company's financial health. Users can select to view data from four periods of either annual or quarterly information, allowing them to track financial performance of Relief Therapeutics Holding SA over time.

Relief Therapeutics Holding SA reported earnings results for the half year ended June 30, 2024. For the half year, the company reported sales was CHF 5.58 million compared to CHF 3.02 million a year ago. Revenue was CHF 5.65 million compared to CHF 3.09 million a year ago. Net loss was CHF 4.56 million compared to CHF 56.5 million a year ago. Basic loss per share from continuing operations was CHF 0.363 compared to CHF 5.098 a year ago. Diluted loss per share from continuing operations was CHF 0.363 compared to CHF 5.098 a year ago.

AnnualQuarterly  
Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

RLFTF Income Statement

Gross margin TTM 68.56%
Operating margin TTM -143.38%
Net Profit margin TTM -537.79%
Return on Investment TTM -13.92%
 Total Revenue  Net Income
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Total Revenue 1.5 1.5 1.51 1.51
Gross Profit 0.98 0.98 1.08 1.08
Operating Income -4.12 -4.12 -5.8 -5.8
Net Income -28.25 -28.25

RLFTF Balance Sheet

Quick Ratio MRQ 2.45
Current Ratio MRQ 3.09
LT Debt to Equity MRQ -
Total Debt to Equity MRQ 4.91%
 Total Assets  Total Liabilities
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Total Assets 125.78 125.78
Total Liabilities 24.16 31.41 31.41
Total Equity 94.37 94.37

RLFTF Cash Flow Statement

Cash Flow/Share TTM -0.82
Revenue/Share TTM 0.69
Operating Cash Flow  -
 Cash  Net Change in Cash
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities -5.23 -5.23
Cash From Investing Activities -0.11 -0.11
Cash From Financing Activities 2.09 2.09
Net Change in Cash -3.22 -3.22
* In Millions of CHF (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

RLFB Comments

Write your thoughts about RELIEF THERAPEUTICS Holding SA
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Carlos Medina
Carlos Medina Jan 05, 2022 10:54AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Reason for the spike? Still pump and dump?
Reply
0 0
Report
Laurent Loboss Badoud
Laurent Loboss Badoud Jan 05, 2022 10:54AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Relief Therapeutics: Nrx wants to patent its anti-COVID formulation of aviptadil
Reply
1 0
Report
Marco Singarella
Marco Singarella Jan 05, 2022 10:54AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Still pump and dump. Is it now a good time to buy?
Reply
0 0
Report
Mohamed Nedif
Mohamed Nedif Nov 12, 2021 3:35AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
https://www.relieftherapeutics.com/newsblog/relief-reports-that-its-u-s-collaboration-partner-has-announced-it-has-received-a-u-s-food-and-drug-administration-review-of-aviptadil-manufacturing-information
Reply
0 0
Report
Carlos Medina
Carlos Medina Oct 20, 2021 11:21AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
With the lawsuit it's pretty much the end for this thing, right?
Reply
0 0
Report
Marco Singarella
Marco Singarella Oct 20, 2021 11:21AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Which lawsuit?
Reply
0 0
Report
Marco Singarella
Marco Singarella Oct 20, 2021 11:21AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Just found this now. Yes sounds the end
Reply
1 0
Report
Marco Singarella
Marco Singarella Sep 22, 2021 3:32AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
good time to buy now. will definitely go up in the next few weeks
Reply
2 0
Report
Carlos Medina
Carlos Medina Sep 22, 2021 3:32AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Based on?
Reply
0 0
Report
Jaroslav Kovacik
Jaroslav Kovacik Sep 07, 2021 10:03AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
2q 2022 gona bi big
Reply
2 0
Report
Douglas Boggs
Douglas Boggs Jul 29, 2021 7:47AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Lots of potential but Still no revenue to report
Reply
1 1
Report
Carlos Medina
Carlos Medina Jul 29, 2021 6:06AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
This stock is puzzling. No updates, suddenly up 20.30% out of the blue. This week, it's secured more funding, completed acquisitions, Aviptadil gets approval in Georgia plus commercial formulation... and the stock is down about 6-7% .... SMH x-/
Reply
0 0
Report
Carlos Medina
Carlos Medina Jul 27, 2021 3:08PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Ok this is bigNRx Pharmaceuticals Announces Emergency Use Authorization of ZYESAMI™ (aviptadil) in Nation of Georgia
Reply
1 0
Report
Jason Conway
Jason Conway Jul 27, 2021 3:08PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Turns out it wasn’t that big…
Reply
0 0
Report
Krava Tsakosh
Krava Tsakosh Jun 08, 2021 10:48AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
That's a nice start of the week
Reply
0 0
Report
Carlos Medina
Carlos Medina May 21, 2021 12:08PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
This stock keeps doing this, falls gradually and then it's pumped o and volume another 20% only to fall again due to lack of news and meaningful updates.
Reply
1 1
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Apple
Continue with Google
or
Sign up with Email